Erytech Pharma S.A. (ERYP) Social Stream



Erytech Pharma S.A. (ERYP): $1.15

-0.05 (-4.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ERYTECH PHARMA SA (ERYP) Price Targets From Analysts

Use the tables below to see what analysts covering ERYTECH PHARMA SA think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-02 2 $3.2 $3.2 $3.2 $1.38 131.88%
NA 1 $NA $NA $NA $1.38 NA%

Price Target Last Issued NA NA, NA

The Trend in the Analyst Price Target


Over the past 14 months, ERYP's average price target has gone down $18.97.

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential

ERYP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 2 0 0 2

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • ERYTECH PHARMA SA's number of analysts covering the stock is higher than 3.41% of all US stocks.
  • To contextualize these metrics, consider that out of all US stocks, ERYTECH PHARMA SA's variance in analysts' estimates is lower than nearly 100% of them.
  • In the context of Healthcare stocks, ERYTECH PHARMA SA's average analyst price target is greater than 3.36% of them.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, ERYTECH PHARMA SA's upside potential (average analyst target price relative to current price) is greater than 59.14% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ERYTECH PHARMA SA are SLDB, XFOR, and APTO.

Is ERYP a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6164 seconds.